FCACT033771_20160310.pdf
INNOVATIVE IMMUNOTHERAPIES TO FIGHT
INFECTIOUS DISEASES AND CANCER

<<

PRESS RELEASE
Paris and Toulouse, March 10, 2016

GENTICEL UPDATES ITS FINANCIAL CALENDAR FOR 2016 AND ANNOUNCES
PARTICIPATION IN KEY CONFERENCES IN H1 2016
GENTICEL (Euronext Paris and Brussels: FR0011790542 – GTCL), a French biotechnology company and leading
developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), updates
its financial calendar for 2016 and announces schedule of participation in key conferences during the first half of
2016.

FINANCIAL CALENDAR 2016 (UPDATED)
March 14

2015 Annual Results
(before Euronext market opening)

April 28

Business & Cash Position Update 1st Quarter 2016

June 9

Annual General Meeting in Paris

July 28

Business & Cash Position Update 2nd Quarter 2016

September 22

2016 Half-Year Results

October 27

Business & Cash Position Update 3rd Quarter 2016

This financial calendar is for indicative purposes only and Genticel could change its publication dates if deemed
necessary.

INVESTOR RELATIONS CONFERENCES
March 14

Paris

SFAF meeting on 2015 annual results and 2016 outlook
(French Society of Financial Analysts)

March 22

Brussels

KBC Securities Healthcare Conference

April 11-12

Paris

Small & Midcap Event

April 16

Antwerp

VFB Happening 2016 (Flemish Federation of Investors)

June 29-30

Paris

Spring Midcap Event

BUSINESS DEVELOPMENT & SCIENTIFIC CONFERENCES
March 21-23

Washington, DC

Targeted Anticancer Therapies (TAT) 2016 Congress

April 4-6

Stockholm

Bio-Europe Spring 2016

June 3-7

Chicago, IL

American Society Of Clinical Oncology (ASCO) 2016
Annual meeting

June 6-9

San Francisco

2016 BIO International Convention

June 15-18

Salzburg

EUROGIN 2016

This conference calendar is for information purposes only.

1

About Genticel
Aiming to solve a public health issue.
Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and
275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early
stage with GTL001, its first-in-class immunotherapeutic candidate. The company has already completed patient recruitment for the phase 2 clinical
trial of GTL001 in Europe.
Offering a promising technological platform.
Genticel’s versatile platform, Vaxiclase, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases.
Genticel’s second candidate, GTL002, is a multivalent HPV immunotherapeutic candidate designed with Vaxiclase. It targets the six most relevant
HPV types in terms of global epidemiology and is currently in preclinical development.
Focusing on value creation.
Respectively, the peak sales potentials of GTL001 and GTL002 are estimated at over €1 billion and €2 billion per year. In addtion to this attractive
HPV product pipeline, Genticel’s versatile technological platform, Vaxiclase, has already generated significant interest in the pharmaceutical
industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SIIL), the world’s largest producer of
vaccine doses. This partnership could generate up to $57 million in revenues for Genticel, before royalties on sales. It will enable SIIL to develop
acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.
For more information, visit us at www.genticel.com

Disclaimer
This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genticel shares in any country. This press release may contain
forward-looking statements by the company with respect to its objectives. These statements are based on the current estimates and forecasts of the company’s management
and are subject to risks and uncertainties such as the company’s ability to implement its chosen strategy, customer market trends, changes in technologies and in the
company’s competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company’s growth. These factors as well as other risks and
uncertainties may prevent the company from achieving the objectives outlined in the press release. No guarantee is given on forward-looking statements which are subject
to a number of risks, notably those described in the registration document filed with the French Markets Authority (the AMF) on 1 April 2015 under number R.15-015 and
those linked to changes in economic conditions, the financial markets, or the markets on which Genticel is present. Genticel products are currently used for clinical trials only
and are not otherwise available for distribution or sale.

GENTICEL

Valerie Leroy
Investor Relations & Corporate
Communications
+ 33 6 33 34 37 30
investors@genticel.com

INVESTORS

MEDIA

US – Life Sci Advisors
Brian Ritchie
+1 212 915 2578
britchie@lifesciadvisors.com
Europe- ACTUS
Corinne Puissant
+33 1 53 67 36 77
cpuissant@actus.fr

2

ALIZE RP
Caroline Carmagnol et
Florence Portejoie
+33 6 64 18 99 59 / +33 6 47 38 90 04
genticel@alizerp.fr

